Rethinking the Food and Drug Administration's 2013 guidance on developing drugs for early-stage Alzheimer's disease - PubMed (original) (raw)

Rethinking the Food and Drug Administration's 2013 guidance on developing drugs for early-stage Alzheimer's disease

Lon S Schneider. Alzheimers Dement. 2014 Mar.

Abstract

The February 2013 Food and Drug Administration (FDA) draft guidance for developing drugs for early-stage Alzheimer's disease (AD) creates certain challenges as they guide toward the use of one cognitive outcome to gain accelerated marketing approval for preclinical AD drugs, and a composite clinical scale - the Clinical Dementia Rating Scale in particular - for the primary outcome for prodromal AD clinical trials. In light of the developing knowledge regarding early stage diagnoses and clinical trials outcomes, we recommend that FDA describe its requirements for validating preclinical AD diagnoses for drug development purposes, maintain the principle for requiring coprimary outcomes, and encourage the advancement of outcomes for early stage AD trials. The principles for drug development for early stage AD should not differ from those for clinical AD, especially as the diagnoses of prodromal and early AD impinge on each other. The FDA should not recommend that a composite scale be used as a sole primary efficacy outcome to support a marketing claim unless it requires that the cognitive and functional components of such a scale are demonstrated to be individually meaningful. The current draft guidelines may inadvertently constrain efforts to better assess the clinical effects of new drugs and inhibit innovation in an area where evidence-based clinical research practices are still evolving.

Keywords: Amyloid; Biomarkers; Clinical Dementia Rating Scale; Clinical outcomes; Clinical trials; Composite scales; Diagnostic criteria; Disease modification; Drug development; Food and Drug Administration; Mild cognitive impairment; Neuropsychological tests; Preclinical Alzheimer's disease; Prodromal Alzheimer's disease; Regulatory guidance.

PubMed Disclaimer

References

1. United States Food and Drug Administration. [accessed June 30, 2013];Guidance for Industry Alzheimer’s Disease: Developing Drugs for the Treatment of Early Stage Disease (FDA-2013-D-0077) DRAFT. 2013 Feb; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati....
1. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & dementia : the journal of the Alzheimer’s Association. 2011;7(3):270–9. -PMC -PubMed
1. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer’s disease: a new lexicon. The Lancet Neurology. 2010;9(11):1118–27. -PubMed
1. Transcript from FDA Webinar: Draft Guidance For Industry On Alzheimer’s disease: Developing Drugs for the Treatment of Early Stage Disease. [accessed October 20 2013];2013 Mar 28; http://www.fda.gov/training/guidancewebinars/ucm367786.htm.
1. Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66(12):1837–44. -PubMed

Rethinking the Food and Drug Administration's 2013 guidance on developing drugs for early-stage Alzheimer's disease - PubMed (original) (raw)